The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients

Arwa M Amin; Lim Sheau Chin; Dzul Azri Mohamed Noor; Hamza Mostafa; Muhamad Ali S K Abdul Kader; Yuen Kah Hay; Baharudin Ibrahim

doi:10.1016/j.thromres.2017.07.032

The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients

Thromb Res. 2017 Oct:158:22-24. doi: 10.1016/j.thromres.2017.07.032. Epub 2017 Aug 1.

Authors

Arwa M Amin¹, Lim Sheau Chin², Dzul Azri Mohamed Noor², Hamza Mostafa², Muhamad Ali S K Abdul Kader³, Yuen Kah Hay², Baharudin Ibrahim²

Affiliations

¹ School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia. Electronic address: arwa.amin.m@gmail.com.
² School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
³ School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia; Cardiology Department, Hospital Pulau Pinang, Penang, Malaysia.

PMID: 28802144
DOI: 10.1016/j.thromres.2017.07.032

No abstract available

Keywords: CYP2C19; Clopidogrel; Coronary artery disease patients; Dual antiplatelet therapy (DAPT); High on treatment platelets reactivity; VerifyNow.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Asian People / genetics
Blood Platelets / drug effects*
Clopidogrel
Coronary Artery Disease / blood
Coronary Artery Disease / enzymology
Coronary Artery Disease / genetics*
Cytochrome P-450 CYP2C19 / genetics*
Female
Humans
Male
Platelet Aggregation Inhibitors / pharmacology*
Polymorphism, Genetic
Ticlopidine / analogs & derivatives*
Ticlopidine / pharmacology

Substances

Platelet Aggregation Inhibitors
Clopidogrel
CYP2C19 protein, human
Cytochrome P-450 CYP2C19
Ticlopidine